Angelica Welch

Articles

Study Addresses Breast Cancer Monitoring Burden on Metastatic Patients

January 2nd 2019

Melissa K. Accordino, MD, MS, discusses ways to improve the monitoring of patients with metastatic breast cancer.

Expert Reflects on 2018 Lung Cancer Advancements

January 2nd 2019

Joshua K. Sabari, MD, reflects on the rapidly advancing landscape of lung cancer.

Fixed-Duration Venetoclax Triplet Active in CLL

January 1st 2019

Kerry A. Rogers, MD, discusses phase II findings of a trial with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in chronic lymphocytic leukemia.

Pembrolizumab Plus BL-8040 Shows Promise in Pancreatic Cancer

December 29th 2018

Manuel Hidalgo, MD, PhD, discusses the potential with BL-8040 and pembrolizumab in pancreatic adenocarcinoma.

Relapsed/Refractory Myeloma Landscape Slated to Expand

December 20th 2018

Samir Parekh, MD, discusses the excitement of selinexor and venetoclax (Venclexta) as possible additions to the myeloma treatment landscape

Infigratinib Active in Intrahepatic Cholangiocarcinoma

December 19th 2018

The selective pan-FGFR kinase inhibitor infigratinib showed meaningful antitumor activity and a manageable safety profile in patients with previously treated intrahepatic cholangiocarcinoma who harbor FGFR2 fusions.

Pemigatinib Emerging as Potential Second-Line Treatment for Cholangiocarcinoma

December 19th 2018

The potent FGFR1-3 inhibitor pemigatinib showed preliminary efficacy and safety signals in the phase II FIGHT-202 trial (NCT02924376) of patients with previously treated advanced, metastatic or surgically unresectable cholangiocarcinoma.

Cholangiocarcinoma Emerges as Key Target of FGFR Inhibitor Research

December 19th 2018

Sameek Roychowdhury, MD, PhD, discusses the potential for FGFR inhibitors in the treatment of patients with cholangiocarcinoma who harbor FGFR fusions.

Expert Reflects on Recent Pivotal Data in RCC

December 18th 2018

Daniel J. George, MD, discusses the status of treatment for patients with high-risk stage III RCC, as well as the role of sunitinib (Sutent) and checkpoint inhibitors in the RCC paradigm.

Eryaspase May Provide Second-Line Option in Pancreatic Cancer

December 18th 2018

Pascal Hammel, MD, PhD, discusses the potential for eryaspase, and the future direction of the pancreatic cancer landscape.

x